Liminal BioSciences regains Nasdaq compliance

Liminal BioSciences announced that it has received written notice from The Nasdaq Stock Market that the company has regained compliance with Nasdaq’s minimum bid price for continued listing on the Nasdaq Capital Market. The notice indicated that, as a result of the closing bid price of the company’s common stock having been $1.00 per share or greater for at least ten consecutive business days, from February 1, 2023 through February 14, 2023, the xompany has regained compliance with Nasdaq Listing Rule 5450(a)(1).